iSpecimen Statistics
Total Valuation
iSpecimen has a market cap or net worth of $4.34 million. The enterprise value is $1.78 million.
Important Dates
The last earnings date was Monday, May 18, 2026, before market open.
| Earnings Date | May 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
iSpecimen has 1.44 million shares outstanding. The number of shares has increased by 531.47% in one year.
| Current Share Class | 1.44M |
| Shares Outstanding | 1.44M |
| Shares Change (YoY) | +531.47% |
| Shares Change (QoQ) | +77.07% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 1.00% |
| Float | 1.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.22 |
| Forward PS | n/a |
| PB Ratio | 2.75 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.73 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.62, with a Debt / Equity ratio of 0.31.
| Current Ratio | 0.62 |
| Quick Ratio | 0.53 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -894.59% and return on invested capital (ROIC) is -406.47%.
| Return on Equity (ROE) | -894.59% |
| Return on Assets (ROA) | -91.78% |
| Return on Invested Capital (ROIC) | -406.47% |
| Return on Capital Employed (ROCE) | -978.02% |
| Weighted Average Cost of Capital (WACC) | 12.43% |
| Revenue Per Employee | $146,785 |
| Profits Per Employee | -$1.59M |
| Employee Count | 7 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -93.96% in the last 52 weeks. The beta is 1.62, so iSpecimen's price volatility has been higher than the market average.
| Beta (5Y) | 1.62 |
| 52-Week Price Change | -93.96% |
| 50-Day Moving Average | 4.75 |
| 200-Day Moving Average | 19.47 |
| Relative Strength Index (RSI) | 33.72 |
| Average Volume (20 Days) | 255,725 |
Short Selling Information
The latest short interest is 112,840, so 7.85% of the outstanding shares have been sold short.
| Short Interest | 112,840 |
| Short Previous Month | 51,489 |
| Short % of Shares Out | 7.85% |
| Short % of Float | 7.85% |
| Short Ratio (days to cover) | 0.07 |
Income Statement
In the last 12 months, iSpecimen had revenue of $1.03 million and -$11.10 million in losses. Loss per share was -$59.74.
| Revenue | 1.03M |
| Gross Profit | -304,522 |
| Operating Income | -9.88M |
| Pretax Income | -11.10M |
| Net Income | -11.10M |
| EBITDA | -9.68M |
| EBIT | -9.88M |
| Loss Per Share | -$59.74 |
Full Income StatementBalance Sheet
The company has $2.82 million in cash and $254,989 in debt, with a net cash position of $2.56 million or $1.78 per share.
| Cash & Cash Equivalents | 2.82M |
| Total Debt | 254,989 |
| Net Cash | 2.56M |
| Net Cash Per Share | $1.78 |
| Equity (Book Value) | 814,038 |
| Book Value Per Share | 1.10 |
| Working Capital | -2.12M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$6.51 million and capital expenditures -$454, giving a free cash flow of -$6.51 million.
| Operating Cash Flow | -6.51M |
| Capital Expenditures | -454 |
| Depreciation & Amortization | 197,447 |
| Net Borrowing | n/a |
| Free Cash Flow | -6.51M |
| FCF Per Share | -$4.53 |
Full Cash Flow StatementMargins
| Gross Margin | -29.64% |
| Operating Margin | -961.36% |
| Pretax Margin | -1,080.72% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
iSpecimen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -531.47% |
| Shareholder Yield | -531.47% |
| Earnings Yield | -255.85% |
| FCF Yield | -149.92% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 118.33% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 28, 2026. It was a reverse split with a ratio of 1:40.
| Last Split Date | Apr 28, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
iSpecimen has an Altman Z-Score of -22.67 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -22.67 |
| Piotroski F-Score | 2 |
